Fecal Incontinence - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 39 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Fecal Incontinence - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Fecal Incontinence - Pipeline Review, H1 2015', provides an overview of the Fecal Incontinence's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fecal Incontinence, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fecal Incontinence and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fecal Incontinence
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fecal Incontinence and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fecal Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fecal Incontinence pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fecal Incontinence
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fecal Incontinence pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fecal Incontinence Overview 6
Therapeutics Development 7
Pipeline Products for Fecal Incontinence - Overview 7
Pipeline Products for Fecal Incontinence - Comparative Analysis 8
Fecal Incontinence - Therapeutics under Development by Companies 9
Fecal Incontinence - Pipeline Products Glance 10
Clinical Stage Products 10
Fecal Incontinence - Products under Development by Companies 11
Fecal Incontinence - Companies Involved in Therapeutics Development 12
Celogos 12
Cook MyoSite Incorporated 13
Innovacell Biotechnologie AG 14
Norgine B.V. 15
RDD Pharma Ltd. 16
S.L.A. Pharma AG 17
Fecal Incontinence - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ICEF-15 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
methoxamine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
oxymetazoline hydrochloride - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
phenylephrine hydrochloride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
phenylephrine hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RCD-2 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Stem Cell Therapy for CAD, Urinary Incontinence and Fecal Incontinence - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Fecal Incontinence - Recent Pipeline Updates 35
Fecal Incontinence - Dormant Projects 36
Fecal Incontinence - Product Development Milestones 37
Featured News & Press Releases 37
Mar 27, 2014: Norgine And Innovacell Dose First Patient In Phase IIb Clinical Trial Of ICEF15, A Personalised Cell Therapy To Treat Faecal Incontinence 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39

List of Tables
Number of Products under Development for Fecal Incontinence, H1 2015 7
Number of Products under Development for Fecal Incontinence - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 10
Products under Development by Companies, H1 2015 11
Fecal Incontinence - Pipeline by Celogos, H1 2015 12
Fecal Incontinence - Pipeline by Cook MyoSite Incorporated, H1 2015 13
Fecal Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2015 14
Fecal Incontinence - Pipeline by Norgine B.V., H1 2015 15
Fecal Incontinence - Pipeline by RDD Pharma Ltd., H1 2015 16
Fecal Incontinence - Pipeline by S.L.A. Pharma AG, H1 2015 17
Assessment by Monotherapy Products, H1 2015 18
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 20
Number of Products by Stage and Route of Administration, H1 2015 22
Number of Products by Stage and Molecule Type, H1 2015 24
Fecal Incontinence Therapeutics - Recent Pipeline Updates, H1 2015 35
Fecal Incontinence - Dormant Projects, H1 2015 36